Doxorubicin–transferrin conjugate alters mitochondrial homeostasis and energy metabolism in human breast cancer cells

Doxorubicin (DOX) is considered one of the most powerful chemotherapeutic agents but its clinical use has several limitations, including cardiomyopathy and cellular resistance to the drug. By using transferrin (Tf) as a drug carrier, however, the adverse effects of doxorubicin as well as drug resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Wigner, Paulina, Zielinski, Krzysztof, Labieniec-Watala, Magdalena, Marczak, Agnieszka, Szwed, Marzena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907108/
https://www.ncbi.nlm.nih.gov/pubmed/33633284
http://dx.doi.org/10.1038/s41598-021-84146-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907108/
https://www.ncbi.nlm.nih.gov/pubmed/33633284
http://dx.doi.org/10.1038/s41598-021-84146-4

Ejemplares similares